IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the
active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in
patients with hormone receptor-positive metastatic breast cancer.